@wellnessnursecourtnay's GLP-1 info access claims, reviewed

What did @wellnessnursecourtnay actually say?

The creator, identifying herself as a nurse, directed viewers to a third-party telehealth platform called Orderly Meds using a referral code. She quoted specific prices: "three months of sema for 199 or three months of ters for 424." She framed this as anti-gatekeeping, presenting the referral as a public service rather than a promotion. Whether she has a financial relationship with Orderly Meds is not disclosed in the clip.

"Sema" and "ters" almost certainly refer to compounded semaglutide and tirzepatide, not FDA-approved brand-name products like Wegovy or Zepbound. That distinction matters enormously and she did not make it. At those price points, these cannot be Novo Nordisk or Eli Lilly products. Compounded versions are a different regulatory category entirely.

Does the science back this up?

The underlying drugs have strong clinical evidence. Semaglutide and tirzepatide are among the best-studied weight-loss medications in recent history. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide producing up to 20.9% mean body weight reduction. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4 mg producing roughly 14.9% weight loss versus placebo.

But that evidence is for the FDA-approved, manufacturer-produced formulations, not compounded versions. The FDA has repeatedly warned that compounded drugs are not FDA-approved and have not been evaluated for safety, efficacy, or quality equivalence. In 2025, the FDA declared the shortage of semaglutide resolved, triggering restrictions on compounding. Tirzepatide's shortage status has been similarly contested. This regulatory context is completely absent from the video.

What did they get wrong (or right)?

She got something right: access to GLP-1 medications is a real and serious barrier. Brand-name Wegovy can cost over $1,300 per month without insurance. Pointing people toward lower-cost options is a legitimate concern. Credit where it is due.

What she got wrong is significant. She did not disclose whether this is a paid partnership or affiliate arrangement, which is an FTC requirement for material connections. She did not clarify that these are compounded drugs, not FDA-approved branded medications. She did not mention that compounded semaglutide and tirzepatide face active FDA scrutiny, ongoing legal battles between compounding pharmacies and manufacturers, and real quality-control variability. The American Society of Health-System Pharmacists and FDA guidance both note that compounded drugs can vary in potency and sterility. A nurse promoting these products without that context is not neutral information sharing. It is incomplete at best.

What should you actually know?

Compounded semaglutide and tirzepatide are legal in certain contexts but sit in a gray zone that is actively shrinking. The FDA has moved to restrict 503A and 503B pharmacy compounding of these drugs as brand-name shortages are declared resolved. Some patients currently on compounded versions may lose access.

Quality is not guaranteed. Unlike FDA-approved products, compounded drugs are not subject to the same manufacturing controls. A 2023 FDA advisory flagged reports of dosing errors with compounded semaglutide, some involving serious adverse events. Telehealth platforms vary widely in the rigor of their prescribing practices. Some require comprehensive intake forms and provider review; others are closer to checkbox medicine.

If you are considering a compounded GLP-1, ask your provider specifically whether the pharmacy is 503A or 503B accredited, what the drug's potency testing results show, and how they handle adverse events. And if a TikTok nurse with a referral code is your primary source of medical guidance, that is a signal to slow down, not speed up.